Latest Breaking News On - Theodore laetsch - Page 2 : comparemela.com

Novartis Pharma AG: Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

Novartis Pharma AG: Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesBaja californiaTheodore laetschRichard jarvisSloan simpsonParag mahantiIsabella zinckMichael meoTina deignanSatoshi sugimotoDennis riedlMarlena abdinoorJonathan grahamNicole zinsli sommImke kappesExchange commission

FDA Approves Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs

The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR–positive GEP-NETs.

United statesTheodore laetschDevelopmental therapeutics programGep netsLutetium lu 177 dotatate

Novartis radioligand therapy Lutathera® FDA approved as

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17).

United statesBaja californiaIsabella zinckTheodore laetschMichael meoTina deignanMarlena abdinoorNicole zinsli sommRichard jarvisSatoshi sugimotoParag mahantiSloan simpsonJonathan grahamImke kappesExchange commissionDevelopmental therapeutics program

FDA Approves Lutathera for Pediatric Patients With SSTR+ Gastroenteropancreatic Neuroendocrine Tumors

This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.

United statesTheodore laetschTina deignanDevelopmental therapeutics programOlivier le moalEvaluate safetyAdolescent patients withAdvanced acceleratorTherapeutic area headMet primary endpointsProgression free survivalGastroenteropancreatic neuroendocrine

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBaja californiaMichael meoTina deignanTheodore laetschIsabella zinckRichard jarvisMarlena abdinoorNicole zinsli sommSloan simpsonParag mahantiSatoshi sugimotoImke kappesJonathan grahamElsevier incDrug administration